ArticleFrontiers in cellular and infection microbiology2017
Oral Multiple Sclerosis Drugs Inhibit the
Article in Frontiers in cellular and infection microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 64 citations in OpenAlex.
- The multiple sclerosis drug fingolimod induces pore-like membrane defects, contributing to its antimicrobial activity.The Journal of biological chemistry · 2026Article
- Multiple Sclerosis Drug Fingolimod Exhibits Antibacterial Activity through Bacterial Membrane Permeabilization.bioRxiv : the preprint server for biology · 2026Article
- Gut microbiota and gut-derived metabolites in defining multiple sclerosis phenotypic continuum.Frontiers in immunology · 2026Review
- Unraveling multiple sclerosis: a hidden interaction between intestinal microbiota and host lipid metabolism.Gut microbes · 2025Review
- Fingolimod potentiates the antifungal activity of fluconazole against fluconazole-resistantFrontiers in cellular and infection microbiology · 2025Article
- The link between gut microbiota and multiple sclerosis from the perspective of barrier function.Frontiers in immunology · 2025Review
- FTY720 Reduces the Biomass of Biofilms inAntibiotics (Basel, Switzerland) · 2024Article
- Multiple Sclerosis andBiomedicines · 2024Article
- The effect of multiple sclerosis therapy on gut microbiota dysbiosis: a longitudinal prospective study.Microbial cell (Graz, Austria) · 2024Article
- Impact of Disease-Modifying Therapies on Gut-Brain Axis in Multiple Sclerosis.Medicina (Kaunas, Lithuania) · 2023Review
- Review
- IsMultiple sclerosis (Houndmills, Basingstoke, England) · 2023Review
- Dimethyl Fumarate and Intestine: From Main Suspect to Potential Ally against Gut Disorders.International journal of molecular sciences · 2023Review
- Multiple Sclerosis-Related Dietary and Nutritional Issues: An Updated Scoping Review with a Focus on Pediatrics.Children (Basel, Switzerland) · 2023Article
- Clostridium epsilon toxin is excessive in multiple sclerosis and provokes multifocal lesions in mouse models.The Journal of clinical investigation · 2023Article
- Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple Sclerosis.International journal of molecular sciences · 2023Article
- New and Old Horizons for an Ancient Drug: Pharmacokinetics, Pharmacodynamics, and Clinical Perspectives of Dimethyl Fumarate.Pharmaceutics · 2022Review
- MetaLP: An integrative linear programming method for protein inference in metaproteomics.PLoS computational biology · 2022Article
- Convergent pathways of the gut microbiota-brain axis and neurodegenerative disorders.Gastroenterology report · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are currently three oral medications approved for the treatment of multiple sclerosis (MS). Two of these medications, Fingolimod, and Teriflunomide, are considered to be anti-inflammatory agents, while dimethyl fumarate (DMF) is thought to trigger a robust antioxidant response, protecting vulnerable cells during an MS attack. We previously proposed that epsilon toxin from the gut bacterium,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.